Angiotensin receptor blockade in the challenging era of systolic hypertension

Journal of Human Hypertension

Volumn 18, Issue 12, 2004, Pages 837-847

  Stergiou, G S ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Angiotensin receptor blockers; Antihypertensive drugs; Arterial compliance; Arterial stiffness; Pulse pressure; Renin angiotensin system; Systolic hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PROPRANOLOL; RESERPINE; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ARTERIOSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL PRACTICE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMORAL ARTERY; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOMES RESEARCH; PATHOGENESIS; PREDICTION; PULSE PRESSURE; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 10044243517     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001762     Document Type: Review

References (117)

1. Guidelines Committee. European Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
2. Chobanian A et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. Hypertension 2003; 42: 1206-1252.
3. 3 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 2003; 21: 1983-1992.
4. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571-1576.
5. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens 1999; 17(Suppl 2): S7-S13.
6. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138: 205-210.
7. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
8. 9 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 1989; 7: 689-693.
9. The 1988 Report of the Joint National committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1988; 148: 1023-1038.
10. Franklin SS et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 10: 354-360.
11. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615.
12. Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB. Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens 1997; 10: 634-639.
13. Petrovitch H, Curb D, Bloom-Marcus E. Isolated systolic hypertension and risk of stroke in Japanese-American men. Stroke 1995; 26: 25-29.
14. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
15. Staessen JA et al. For the Systolic Hypertension in Europe Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 650: 757-764.
16. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens 2001; 3: 211-216.
17. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479-486.
18. Berlowitz DR et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339 1957-1963.
19. Oliveria SA et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413-420.
20. Fagard RH, Van Den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297-1302.
21. Stergiou GS, Karotsis AK, Symeonidis A, Vassilopoulou VA, for the ABC-GP Study Group. Aggressive blood pressure Control in General Practice (ABC-GP) study: can the new targets be reached? J Hum Hypertens 2003; 17: 767-773.
22. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 1461-1464.
23. Julius S et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-548.
24. Benetos A. Pulse pressure and cardiovascular risk. J Hypertens 1999; 17(Suppl 5): S21-S24.
25. Blacher J et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085-1089.
26. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401.
27. Fang J, Madhavan S, Cohen H, Alderman MH. Measures of blood pressure and myocardial infarction in treated hypertensive patients. J Hypertens 1995; 13: 413-419.
28. Millar JA, Lever AF. Pulse pressure predicts coronary but not cerebrovascular events in placebo-treated male subjects of MRC trial. J Hypertens 1996; 14(Suppl 1): S194.
29. Kostis JB et al. Association of increased pulse pressure with the development of heart failure in SHEP. Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group. Am J Hypertens 2001; 14:798-803.
30. Amery A et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1985; 1: 1349-1354.
31. Mitchell GF et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and ventricular enlargement. Circulation 1997; 96: 4254-4260.
32. Benetos A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410-1415.
33. Verdecchia P et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103 2579-2584.
34. Selker HP, Beshansky J, Schmid CH. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90: 1657-1661.
35. Franklin SS et al. The importance of pulsatile components of hypertension in predicting carotid stenosis in older adults. J Hypertens 1997; 15: 1143-1150.
36. Pannier B et al. Pulse pressure and echocardiographic findings in essential hypertension. J Hypertens 1989; 7: 127-132.
37. Pedrinelli R et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35 48-54.
38. Stergiou GS et al. Clinic, home and ambulatory pulse pressure: comparison and reproducibility. J Hypertens 2002; 20 1987-1993.
39. Verdecchia P et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983-988.
40. London GM, Cohn JN. Prognostic application of arterial stiffness. Am J Hypertens 2002; 15: 754-758.
41. Achimastos A et al. Determinants of arterial stiffness in Greek and French hypertensive men. Blood Press 2002; 11: 218-222.
42. O'Rourke MF et al. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 2002; 15: 426-444.
43. Laurent S et al. Clinical applications of arterial stiffness: therapeutics and pharmacology. Am J Hypertens 2002; 15: 453-458.
44. Safar ME, Benetos A. Factors influencing arterial stiffness in systolic hypertension in the elderly: role of sodium and the renin-angiotensin system. Am J Hypertens 2003; 16: 249-258.
45. Van Bortel LM et al. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens 2002; 15: 445-452.
46. Boutouyrie P et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10-15.
47. Laurent S et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
48. Blacher J et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33: 1111-1117.
49. Safar ME, Van Bortel LMAB, Struijker-Boudier HAJ. Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vasc Res 1997; 34: 67-81.
50. Rehman A, Rahman AR, Rasool AH. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT-1) receptors. J Hum Hypertens 2002; 16: 261-266.
51. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864-2869.
52. Mourad JJ et al. Age-related increase of pulse pressure and gene polymorphisms in essential hypertension: a preliminary study. JRAAS 2002; 3: 109-115.
53. Benetos A et al. Influence of the angiotensin type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081-1084.
54. Asmar R et al. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. JRAAS 2002; 3: 176-180.
55. Asmar R, Lacourciere Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000; 18: 1683-1690.
56. Stergiou GS et al. Assessment of drug effects on blood pressure and pulse pressure using measurements in the clinic, at home and with ambulatory monitoring. J Hum Hypertens 2002; 16: 729-735.
57. Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared to lisinopril. J Cardiovasc Pharmacol 2003; 42: 491-496.
58. Delerme S et al. Aortic stiffness is reduced beyond blood pressure lowering by short- and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients (abst). Hypertension 1998; 32: 789.
59. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123.
60. Cockcroft JR, Brown MJ. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet 2002; 359: 2203-2204.
61. Kelly R et al. Arterial dilation and reduced wave reflection: benefit of dilevalol in hypertension. Hypertension 1989; 14: 14-21.
62. Cockcroft JR et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274:1067-1071.
63. Asmar RG et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941-950.
64. Asmar R et al. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001; 19: 813-818.
65. Ghiadoni L et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286.
66. Asmar RG, London GM, O'Rourke ME, Safar ME. REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38: 922-926.
67. London GM, Asmar RG, O'Rourke MF, Safar ME. REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Am Coll Cardiol 2004; 43: 92-99.
68. 1 receptor antagonist, reduces markers of inflammation in patients with early atherosclerosis. J Am Coll Cardiol 2001; 37: 440.
69. Lauten WB et al. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol 2003; 91: 1116-1119.
70. Koh KK et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-910.
71. 1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens 2002; 15 1087-1091.
72. Klemsdal TO, Moan A, Kjeldsen SE. Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press 1999; 8: 214-219.
73. Mahmud A, Feely J. Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002; 15: 1092-1095.
74. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16: 439-444.
75. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609-614.
76. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-325.
77. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
78. Pfeffer MA et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
79. Pitt B et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
80. Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
81. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
82. Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
83. Lewis E et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860,
84. Brenner B et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
85. Parving HH et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
86. Blood Pressure Lowering Treatment Trialists. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
87. Neutel JM et al. The effects of candesartan cilexetil in isolated systolic hypertension: a Clinical Experience Trial. J Clin Hypertens 2000; 2: 181-186.
88. Cushman WC, Brady WE, Gazdick LP, Zeldin RK. The effect of a losartan-based treatment regimen on isolated systolic hypertension. J Clin Hypertens 2002; 4: 101-107.
89. Volpe M et al. Comparison of the blood pressure-lowering effects and tolerability of losartan and amlodipine based regimens in patients with isolated systolic hypertension. Clin Ther 2003; 25: 1469-1489.
90. Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged > or = 65 years with systolic hypertension. Clin Ther 2000; 22: 961-969.
91. Kjeldsen SE et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-1498.
92. Malmqvist K et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-1176.
93. Thurmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
94. Gaudio C et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003; 42: 622-628.
95. Stergiou GS, Skeva II. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences. Curr Top Med Chem 2004; 4: 473-481.
96. Mogensen CE et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
97. Azizi M et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000; 18: 1139-1147.
98. Stergiou GS et al. Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000; 35: 937-941.
99. Stergiou GS et al. Additive effects of an ACE inhibitor versus a calcium antagonist versus a diuretic in hypertensive patients uncontrolled on angiotensin receptor blocker monotherapy. Abstract. J Hypertens 2004; 22(Suppl 2): S318.
100. Sever PS, Chang CL. Discordant responses to two classes of drugs acting on the renin-angiotensin system. JRAAS 2001; 2: 25-30.
101. Stergiou GS et al. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism? Am J Hypertens 2001; 14: 688-693.
102. Stergiou G, Efstathiou S, Roussias L, Mountokalakis T. Intraindividual blood pressure responses to angiotensin converting enzyme inhibition and angiotensin receptor blockade. Am J Hypertens 2004; 17: 123A.
103. Gradman AH et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52-57.
104. Smith DH et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111-117.
105. Kassler-Taub K et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11: 445-453.
106. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-142.
107. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 2981-2997.
108. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907.
109. Conlin PR et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
110. Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens 1999; 21: 1373-1396.
111. Raskin P et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999; 13: 683-687.
112. Kochar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805.
113. Brown MJ et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 1038-1042.
114. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002; 15: 544-549.
115. Farsang C et al. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001; 21: 17-23.
116. Zanchetti A. Contribution of fixed low-dose combinations to initial therapy in hypertension. Eur Heart J 1999; 17(Suppl A): 8-15.
117. Stergiou GS, Malakos JS, Achimastos AD, Mountokalakis TD. Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring. J Cardiovasc Pharmacol 1997; 29: 412-416.